subscribeSubscribe
Galapagos announces first quarter 2023 financial results

Galapagos announces first quarter 2023 financial results
GLOBENEWSWIRE
04 May 2023
Share Share
Galapagos initiates Phase 3 program with filgotinib in patients with AAS

Galapagos initiates Phase 3 program with filgotinib in patients with AAS
GLOBENEWSWIRE
26 Apr 2023
Share Share
Galapagos announces results from PIII trial of filgotinib in Crohn’s disease

Galapagos announces results from PIII trial of filgotinib in Crohn’s disease
PRESS RELEASE
09 Feb 2023
Share Share
EMA backs restrictions on certain immune-regulating drugs

EMA backs restrictions on certain immune-regulating drugs
BIOPHARMADIVE
12 Nov 2022
Share Share
Galapagos announces strategy to accelerate innovation & reports 3Q 2022 results

Galapagos announces strategy to accelerate innovation & reports 3Q 2022 results
PRESS RELEASE
04 Nov 2022
Share Share
JAK inhibitors increase risk of cardiovascular problems and cancer, warns PRAC

JAK inhibitors increase risk of cardiovascular problems and cancer, warns PRAC
Catherine Eckford EUROPEANPHARMACEUTICALREVIEW
01 Nov 2022
Share Share
EMA limits use of JAK inhibitors for at-risk groups in wake of safety concerns

EMA limits use of JAK inhibitors for at-risk groups in wake of safety concerns
Nicole DeFeudis ENDPTS
29 Oct 2022
Share Share
Once daily JYSELECA ®(filgotinib) to be made available on the NHS

Once daily JYSELECA ®(filgotinib) to be made available on the NHS
PHARMIWEB
10 Oct 2022
Share Share
Jyseleca licensed for active ulcerative colitis in Great Britain

Jyseleca licensed for active ulcerative colitis in Great Britain
GLOBENEWSWIRE
18 Jan 2022
Share Share
Jyseleca®?(filgotinib) approved in the European Union for the treatment

Jyseleca®?(filgotinib) approved in the European Union for the treatment
GLOBENEWSWIRE
15 Nov 2021
Share Share